Join the APIS Team at Liverpool Pathology 2023 for the 14th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society.

27-29th June 2023

APIS is leveraging systems biology, interrogating multi-OMICs biodata, and deploying innovative synthetic ‘Clickmer’ high-affinity ligand binding technology, for the validation and translation of biomarker and drug assets into clinical utility.

APIS has deep expertise and capabilities in platform agnostic IVD development of molecular & immunoassays for ultimate product realisation as IVD tests.

The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. This assay can help direct clinicians to the right treatment more quickly with higher accuracy.

The new APIS ESR1 Mutations Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the estrogen receptor gene. The Kit is a qualitative test, detecting eleven ESR1 mutations across exons 5 (E380Q), 7 (S463P) and 8 (P535H, L536R, L536Q, L536H, L536P, Y537C, Y537S, Y537N and D538G).

Interested in learning more? Use this link to contact us and schedule a meeting.